[Acetylcholinesterase inhibitors--beyond Alzheimer's disease].
Based on a literature review, the application of Acetylcholinesterase inhibitors, IAchE (donepezil, rivastigmine, galantanine) in the treatment of various illnesses which have cholinergic system disability and dementia in their course--(dementia with Lewy bodies, vascular dementia, Parkinson's disease, Multiple Sclerosis, Down Syndrome), delirium symptoms (e.g. Korsakoff psychosis), hyperkinesis, attention and memory disorders--is presented. Promising results in the treatment of late dyskinesias, in schizophrenia with impaired cognitive function, as well as in the additional treatment of various psychotic states are noted. It should be stressed that in Poland, the IAchE have been approved only in the treatment of slight to moderate dementia in the course of Alzheimer's disease.
Kłoszewska
Iwona
I
I Klinika Psychiatryczna Katedry Psychiatrii AM w Łodzi.
D000544:Alzheimer Disease / Q000188:drug therapy*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002219:Carbamates / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003704:Dementia / Q000188:drug therapy; D000077265:Donepezil; D004314:Down Syndrome / Q000188:drug therapy; D020820:Dyskinesias / Q000188:drug therapy; D005702:Galantamine / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D020915:Korsakoff Syndrome / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D048448:Phenylcarbamates; D010880:Piperidines / Q000627:therapeutic use; D000068836:Rivastigmine; D012559:Schizophrenia / Q000188:drug therapy
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine